Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

Rhea-AI Summary

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has received TSX Venture Exchange approval to extend the expiration date of 2,029,250 warrants, previously set to expire on June 30, 2021, now extended to January 28, 2022. The warrants allow purchase at $1.20 per share, with all other terms remaining unchanged. This extension follows Avivagen's prior announcement made on June 7, 2021. Avivagen specializes in developing non-antibiotic health products for livestock, supporting immune function and promoting growth.

Positive

• Approval of warrant expiration extension indicates investor confidence.
• OxC-beta™ technology offers an effective alternative to antibiotics in animal feed.
• Strong market potential, with OxC-beta™ Livestock already sold in multiple countries.

Negative

• None.

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017. These warrants previously had an expiration date of June 30, 2021, which has been extended to January 28, 2022.

All other terms and conditions of the warrants remain unchanged. Avivagen previously announced its intention to seek approval of such extension by way of a press release on June 7, 2021.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Copyright © 2021 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc

View source version on businesswire.com: https://www.businesswire.com/news/home/20210611005463/en/

FAQ

What recent approval did Avivagen Inc. receive regarding its warrants?

Avivagen received approval from the TSX Venture Exchange to extend the expiration date of its warrants to January 28, 2022.

What is the new expiration date for Avivagen's warrants?

The new expiration date for Avivagen's warrants is January 28, 2022.

How many common shares can be purchased through Avivagen's warrants?

The warrants are exercisable to purchase 2,029,250 common shares at $1.20 each.

What technology does Avivagen develop for livestock?

Avivagen develops OxC-beta™ technology, a non-antibiotic solution to enhance animal health and growth.

In which countries is OxC-beta™ Livestock available for sale?

OxC-beta™ Livestock is available in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.